Biologics are increasingly being moved to first-line treatment status for certain conditions because mounting clinical evidence suggests they can alter disease trajectories in ways that older conventional therapies simply cannot. For conditions like moderate-to-severe rheumatoid arthritis, psoriasis, and some inflammatory bowel diseases, physicians have historically exhausted a ladder of cheaper, broadly immunosuppressive drugs before turning to biologics. That paradigm is shifting. Rheumatologists, for instance, have reported that starting patients on tumor necrosis factor inhibitors early in the course of rheumatoid arthritis — rather than waiting for methotrexate to fail — can prevent irreversible joint damage that would otherwise accumulate during months of inadequate treatment. This shift matters for brain health and dementia care audiences because neuroinflammation is a growing area of biologic research, and the principles driving first-line biologic use in other fields may eventually reshape how we approach neurological conditions.
Several monoclonal antibodies targeting amyloid-beta plaques have already entered clinical use for early Alzheimer’s disease, and the debate over when to deploy them mirrors what rheumatology and dermatology wrestled with years ago. This article examines why the traditional step-therapy model is being challenged, what conditions are most affected, the limitations and risks involved, and what this evolution might mean for patients with neurodegenerative diseases. Beyond the science, there are economic and regulatory forces at play. The arrival of biosimilars has begun to erode the cost barrier that once made biologics impractical as first-line agents, and updated clinical guidelines from professional societies reflect this new reality. We will walk through the clinical reasoning, the practical tradeoffs, and the areas where caution is still warranted.
Table of Contents
- Why Are Biologics Being Considered Before Traditional Therapies for Some Conditions?
- Which Conditions Have Seen the Strongest Shift Toward First-Line Biologics?
- The Role of Biosimilars in Making First-Line Use Feasible
- How Do Physicians Decide Between Starting with Biologics Versus Conventional Therapy?
- What Are the Risks and Limitations of Early Biologic Use?
- Insurance and Access Barriers to First-Line Biologic Therapy
- What Does the Future Hold for Biologics in Brain Health?
- Conclusion
- Frequently Asked Questions
Why Are Biologics Being Considered Before Traditional Therapies for Some Conditions?
The core argument for first-line biologic use rests on a concept called the “window of opportunity.” In many inflammatory and autoimmune diseases, there is an early period during which aggressive treatment can prevent permanent structural damage — joint erosion in rheumatoid arthritis, bowel stricturing in Crohn’s disease, or skin scarring in severe psoriasis. Conventional disease-modifying drugs like methotrexate, sulfasalazine, or azathioprine work for many patients, but they can take weeks or months to reach full effect. During that lag, disease progression continues. Biologics, which target specific molecules in the inflammatory cascade rather than broadly suppressing the immune system, often achieve faster and more complete disease control. Compare the two approaches in rheumatoid arthritis: a patient started on methotrexate alone may wait three to six months for a meaningful response, and if the drug fails, the physician then escalates to a biologic — a process that can consume a year or more.
During that time, radiographic studies may show new joint erosions. By contrast, clinical trials have demonstrated that patients started on a biologic (sometimes in combination with methotrexate) from the outset showed significantly less structural damage at one and two years. The tradeoff is cost and the potential for side effects from a more potent therapy, but for patients with poor prognostic markers — high inflammatory markers, early erosions, or strong autoantibody positivity — many specialists now argue the risk of undertreating is greater than the risk of the biologic itself. This reasoning does not apply uniformly. For mild disease or patients without poor prognostic indicators, conventional therapies remain appropriate starting points. The shift toward first-line biologics is most pronounced in patients who present with aggressive disease features, where the cost of delayed effective treatment is measured in irreversible tissue damage.
Which Conditions Have Seen the Strongest Shift Toward First-Line Biologics?
Rheumatoid arthritis and moderate-to-severe plaque psoriasis are the two fields where first-line biologic use has gained the most traction in clinical guidelines. In psoriasis, interleukin-17 and interleukin-23 inhibitors have demonstrated skin clearance rates that older systemic therapies like methotrexate and cyclosporine rarely match. Some dermatology guidelines now position these biologics as appropriate initial systemic therapy for patients with moderate-to-severe disease, bypassing the older requirement to fail on conventional agents first. Inflammatory bowel disease, particularly Crohn’s disease with fistulizing or stricturing features, has also seen a move toward early biologic intervention, often with anti-TNF agents. However, the picture is more complicated in neurology. The recent approvals of anti-amyloid monoclonal antibodies for Alzheimer’s disease have introduced biologics into the dementia space, but their positioning is far from settled.
Unlike rheumatoid arthritis, where the relationship between inflammation and joint destruction is well-characterized, the amyloid hypothesis in Alzheimer’s remains debated. The clinical benefits observed in trials of these agents have been statistically significant but modest in absolute terms, and the risk of amyloid-related imaging abnormalities — brain swelling or microbleeds — adds a safety consideration that does not have a clean parallel in rheumatology. If a patient carries the APOE4 gene variant, the risk of these imaging abnormalities increases substantially, which complicates the risk-benefit calculation. Multiple sclerosis represents a middle ground. High-efficacy biologic and biologic-like therapies such as natalizumab, ocrelizumab, and ofatumumab have increasingly been used as first-line agents in patients with aggressive relapsing disease, rather than reserving them for patients who fail on older injectable interferons or glatiramer acetate. Neurologists who favor this approach argue that early, aggressive treatment reduces the accumulation of disability in a disease where lost neurological function is rarely recovered.
The Role of Biosimilars in Making First-Line Use Feasible
One of the most significant barriers to first-line biologic use has always been cost. Originator biologics can carry annual price tags in the tens of thousands of dollars, which made insurers and health systems reluctant to approve them before cheaper alternatives had been tried. The maturation of the biosimilar market is changing this calculus. As patents on early biologics like infliximab, adalimumab, and etanercept have expired, biosimilar versions have entered the market at meaningfully lower prices. In European markets, where biosimilar adoption has been more aggressive, the cost reductions have been substantial enough that some health systems now consider biosimilar TNF inhibitors cost-competitive with prolonged courses of conventional therapy when you factor in the costs of monitoring, managing side effects, and treating disease flares during the step-therapy process.
The United States has been slower to realize these savings due to patent litigation strategies and pharmacy benefit structures, but biosimilar adalimumab products have begun to gain market share, and prices have been trending downward. For the dementia care field specifically, biosimilars are not yet relevant because the anti-amyloid antibodies are still under patent protection and no biosimilar competition exists. This means cost remains a major barrier to broad first-line use in Alzheimer’s disease. A single year of treatment with these agents has been reported to cost tens of thousands of dollars before insurance negotiations, and the infusion infrastructure required adds further expense. Until biosimilar competition arrives — likely not for many years — the economic argument that has helped justify first-line biologics in rheumatology and dermatology does not yet apply to neurology.
How Do Physicians Decide Between Starting with Biologics Versus Conventional Therapy?
The decision is rarely binary. Most clinical guidelines now use a stratified approach, where the severity of disease at presentation, the presence of poor prognostic factors, and the patient’s own preferences and circumstances determine the starting point. In rheumatoid arthritis, a patient presenting with high levels of rheumatoid factor, anti-CCP antibodies, early erosions on imaging, and marked functional limitation might be started on a biologic immediately. A patient with milder inflammatory markers and no erosions would typically begin with methotrexate. This stratification requires reliable biomarkers and prognostic tools, and that is where the comparison to dementia care becomes instructive. Rheumatology benefits from decades of validated prognostic scoring systems.
Alzheimer’s disease is still building this infrastructure. Amyloid PET imaging and cerebrospinal fluid biomarkers can confirm amyloid pathology, but predicting which patients will derive meaningful clinical benefit from amyloid-lowering therapy remains imprecise. A patient with confirmed amyloid plaques and early cognitive symptoms might be a candidate for anti-amyloid therapy, but without robust tools to predict response, the decision involves more uncertainty than the analogous decision in rheumatology. The tradeoff also involves safety monitoring. Biologics require more intensive surveillance than most conventional therapies — regular blood work, screening for latent infections like tuberculosis, and in the case of anti-amyloid antibodies, serial MRI scans to detect brain edema or hemorrhage. For patients in rural areas or those with limited access to specialty care, these monitoring requirements can be a practical barrier to first-line biologic use regardless of what the clinical evidence supports.
What Are the Risks and Limitations of Early Biologic Use?
The most commonly cited risk of biologics as a class is immunosuppression. By targeting specific immune pathways, biologics can increase susceptibility to infections, including serious ones like tuberculosis reactivation, invasive fungal infections, and certain viral reactivations. This risk exists whether the biologic is used first-line or after conventional therapy has failed, but starting a biologic earlier means a longer cumulative exposure over the patient’s lifetime, which may compound infection risk over time. There is also the concern about overtreatment. Not every patient with moderate disease will progress to severe disease. By starting with a biologic, some patients will receive a more expensive and more potent therapy than they ultimately needed.
In conditions like psoriasis, where the consequences of undertreatment are primarily quality-of-life related rather than organ-threatening, some clinicians argue that a trial of conventional therapy is a reasonable and lower-risk starting point. The counterargument is that quality of life matters profoundly, and that months spent on an inadequate therapy represent a real cost to the patient even if no permanent structural damage accrues. In the context of Alzheimer’s disease, the limitations are particularly stark. The anti-amyloid antibodies currently available have shown they can clear amyloid plaques, but the translation of plaque clearance into meaningful cognitive preservation has been modest. Critics have noted that the clinical benefit, measured in points on cognitive scales, may not be perceptible to patients or families in daily life. Combined with the risk of amyloid-related imaging abnormalities — which can occasionally be symptomatic and, rarely, serious — the risk-benefit profile is tighter than in conditions where biologics have more decisively outperformed conventional alternatives.
Insurance and Access Barriers to First-Line Biologic Therapy
Even when clinical guidelines support first-line biologic use, insurance coverage often lags behind. Many payers in the United States still enforce step-therapy protocols, requiring documented failure of one or more conventional agents before approving biologic coverage. These policies are driven by cost management, and while they are rational from a population-level budget perspective, they can delay appropriate treatment for individual patients.
Physicians frequently spend time on prior authorization paperwork and appeals, and patients may endure weeks or months on a therapy their doctor already expects to fail. Some states have enacted step-therapy reform laws that allow physicians to bypass these requirements under certain circumstances — for example, when a patient has a documented contraindication to the conventional agent, or when the condition is severe enough that delay poses a risk of irreversible harm. Patient advocacy organizations in rheumatology, dermatology, and gastroenterology have been active in pushing for these reforms. In the dementia space, access barriers are compounded by the limited number of infusion centers equipped to administer anti-amyloid therapies and the MRI monitoring burden, creating logistical as well as financial obstacles.
What Does the Future Hold for Biologics in Brain Health?
The trajectory in neurology appears to be following the path blazed by rheumatology and oncology, albeit with a significant time lag. As the understanding of neuroinflammation deepens, new biologic targets are emerging beyond amyloid-beta. Therapies targeting tau protein, inflammatory microglia, and complement pathways are in various stages of clinical development. If any of these demonstrate the kind of clear, disease-modifying benefit that TNF inhibitors showed in rheumatoid arthritis, the argument for early biologic intervention in neurodegenerative disease will strengthen considerably.
The key variable will be biomarker development. First-line biologic use in other fields became rational only when physicians could reliably identify, at the point of diagnosis, which patients were likely to have aggressive disease courses. Blood-based biomarkers for Alzheimer’s disease and other dementias are advancing rapidly, and their maturation could eventually enable the same kind of prognostic stratification that guides treatment decisions in rheumatology today. For now, the dementia care field is in an earlier phase of this evolution — one where the tools exist but the evidence base for who benefits most, and when treatment should begin, is still being built.
Conclusion
The movement toward first-line biologic therapy represents a genuine paradigm shift in how physicians approach several chronic diseases, driven by evidence that early intervention with targeted therapies can prevent irreversible damage in ways that older step-therapy models did not achieve. In rheumatology, dermatology, and gastroenterology, this shift is already well underway, supported by clinical trial data, updated guidelines, and the emerging cost relief provided by biosimilars. The central principle — that the window for effective intervention is finite, and that waiting for conventional drugs to fail may waste that window — has broad implications. For those focused on dementia care and brain health, this evolution is worth watching closely.
The anti-amyloid antibodies approved for Alzheimer’s disease are the first biologics to enter the neurodegenerative space, and the debates surrounding their use echo earlier debates in other specialties. The evidence for their clinical benefit is real but modest, the costs are high, and the tools for selecting the right patients are still maturing. As biomarker science advances and as new biologic targets beyond amyloid emerge, the question of when to start treatment — and with what — will become increasingly central to dementia care. Patients and caregivers should discuss these evolving options with neurologists who are tracking the rapidly changing evidence base.
Frequently Asked Questions
What is the difference between a biologic and a traditional drug?
Traditional drugs are typically small molecules made through chemical synthesis, while biologics are large, complex proteins manufactured from living cells. Biologics tend to target specific components of the immune system rather than broadly suppressing immune function. This precision can mean fewer off-target side effects but also comes with unique risks, higher costs, and the requirement for injection or infusion rather than oral dosing.
Are biologics a cure for autoimmune diseases or Alzheimer’s?
No. Biologics for autoimmune conditions like rheumatoid arthritis control the disease but do not cure it — symptoms typically return if the medication is stopped. Similarly, anti-amyloid biologics for Alzheimer’s disease aim to slow cognitive decline, not reverse it. They are disease-modifying in the sense that they alter the underlying biology, but they do not eliminate the disease.
Why do insurance companies require step therapy before approving biologics?
Step therapy policies are primarily cost-management tools. Because biologics are significantly more expensive than conventional therapies, insurers want evidence that cheaper options were tried and failed before covering the costlier drug. While this approach saves money at the population level, it can delay effective treatment for patients whose disease is unlikely to respond to conventional therapy.
What are amyloid-related imaging abnormalities?
These are brain changes visible on MRI scans that can occur in patients receiving anti-amyloid antibody treatments. They include brain edema (swelling) and microhemorrhages (small bleeds). Most cases are asymptomatic and resolve on their own, but in some patients they can cause headaches, confusion, or more serious neurological symptoms. Regular MRI monitoring is required during treatment to detect these changes early.
Can a patient request a biologic as their first treatment?
Patients can discuss this with their physician, and in many cases, if the clinical profile supports it, the doctor may agree. However, insurance approval is a separate hurdle. Even if the physician prescribes a biologic first-line, the insurer may deny coverage until step-therapy requirements are met, requiring an appeal or use of manufacturer assistance programs to cover costs.
